Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

Not Applicable

Completed

• Conditions: Cardiovascular Disease

• Registration Number: NCT00530595
• Lead Sponsor: Saitama Medical University

Brief Summary

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Detailed Description

Not available

Study Timeline

• Status Verified: 2007-09
• Study First Submitted: 2007-09-13
• Study First Submitted QC: 2007-09-14
• Last Update Submitted: 2007-09-14
• Study First Posted: 2007-09-17
• Last Update Posted: 2007-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• 30 to 80 years of age
• Receiving hemodialysis at least 12 months and less than 5 years
• Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion Criteria

• Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL